{"id":3615,"date":"2020-05-06T16:35:08","date_gmt":"2020-05-06T15:35:08","guid":{"rendered":"https:\/\/orbusneich.com\/about-us\/"},"modified":"2026-04-01T17:17:27","modified_gmt":"2026-04-01T09:17:27","slug":"about-us","status":"publish","type":"page","link":"https:\/\/orbusneich.com\/us\/about-us\/","title":{"rendered":"About Us"},"content":{"rendered":"\n
\"\"<\/span>
\n

Our vision is to improve patients\u2019 quality of <\/strong>
life<\/strong>, globally, for those with vascular disease
through our pioneering technologies<\/strong><\/h2>\n<\/div><\/div>\n\n\n\n
\n
\n
\n
\n

Our Mission<\/h3>\n\n\n\n

OrbusNeich designs and delivers innovative solutions for the treatment of vascular disease that improve patients\u2019 quality of life.<\/h4>\n\n\n\n

Our commitment is driven by Integrity<\/strong>, Passion<\/strong>, Innovation,<\/strong> and Performance<\/strong>. These respect the foundation of our core values that shape and reflect the company\u2019s identity.<\/h4>\n\n\n\n

G-70-1095 Rev02<\/p>\n<\/div><\/div>\n<\/div>\n\n\n\n

\n

History<\/h3>\n\n\n\n

OrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, we sell products to over 70 countries and regions worldwide. In addition to PCI\/PTA balloons, we also specialize in coronary stent products and are actively expanding into the area of structural heart disease.<\/p>\n\n\n\n

Our Group\u2019s history traces back to 2000 when Mr. Teddy CHIEN, our Chairman Emeritus and founder, commenced our cardiovascular interventional medical devices business. Mr. Teddy CHIEN has worked with the medical community over the past 50 years in various capacities at pharmaceutical and medical device companies. Mr. Teddy CHIEN first launched Cordis Neich, an exclusive distributor of medical devices for diagnostics and interventional procedures for Cordis Corporation in Asia. After Cordis Corporation and assets of Cordis Neich were acquired by Johnson & Johnson in 1996, Mr. Teddy CHIEN founded our Group to focus on the development and manufacturing of endovascular interventional devices. Mr. Teddy CHIEN also established the Chien Foundation to provide young interventional cardiologists with financial resources and opportunities for training in enhanced techniques in interventional cardiology, with an overall objective to raise the standard of healthcare for the benefit of the general public in countries in Asia-Pacific region. <\/p>\n\n\n\n

Under Mr. Teddy CHIEN\u2019s leadership, we further expanded our research and development and manufacturing capacity in 2005 by acquiring Orbus Medical Technologies Inc., which primarily focuses on developing and manufacturing stents, by way of merger.<\/p>\n\n\n\n

In 2016, Mr. David CHIEN became our CEO. Under his leadership, the Group has grown rapidly through market expansion, market penetration, enriching product offerings and venturing into new business segments. In 2021, the Group opened to third parties for investment for the first time and successfully raised over USD200 million of funds, marking a new chapter for its development.<\/p>\n<\/div>\n<\/div>\n\n\n\n

G-70-1507 Rev02<\/p>\n<\/div><\/div>\n\n\n\n

\n\n\n\n
\n

Key Development Milestones<\/h3>\n\n\n\n

The following table sets forth certain key development milestones of our Group:<\/p>\n\n\n\n

\n
\n

Year<\/h4>\n<\/div>\n\n\n\n
\n

Milestone<\/h4>\n<\/div>\n<\/div>\n\n\n\n
\n
\n

2001<\/strong><\/p>\n<\/div>\n\n\n\n

\n

Our Group launched our R&D, product development and manufacturing base in Shenzhen, the PRC.<\/p>\n\n\n\n

Our Group received our first regulatory approval for our balloon catheter from PMDA in September.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

2005<\/strong><\/p>\n<\/div>\n\n\n\n

\n

Our Group acquired Orbus Medical Technologies Inc. and its subsidiaries for a research and development center in the United States and a manufacturing base in the Netherlands, and expanded our sales network in Europe.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

2007<\/strong><\/p>\n<\/div>\n\n\n\n

\n

Our first generation \u201cSapphire\u201d received CE Mark in April, marking the beginning of our Sapphire balloon catheter product family.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

2008<\/strong><\/p>\n<\/div>\n\n\n\n

\n

Our first generation \u201cScoreFlex\u201d obtained CE Mark in May.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

2016<\/strong><\/p>\n<\/div>\n\n\n\n

\n

Mr. David CHIEN became our CEO, resetting the business strategy of our Group.<\/p>\n\n\n\n

We launched our second generation COMBO Plus dual therapy stent with an advanced delivery system in June.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

2017<\/strong><\/p>\n<\/div>\n\n\n\n

\n

We commenced selling our balloon products in the United States.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

2018<\/strong><\/p>\n<\/div>\n\n\n\n

\n

Jade PTA received FDA 510(k) clearance in February.<\/p>\n\n\n\n

Sapphire II Pro received FDA 510(k) clearance in March and became the first 1.0mm diameter balloon in the United States.<\/p>\n\n\n\n

Teleport, our first microcatheter product, obtained CE Mark and FDA 510(k) clearance in March and November, respectively.<\/p>\n\n\n\n

We commenced worldwide distribution of coronary artery and peripheral orbital atherectomy products for a United States medical device developer and manufacturer.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

2019<\/strong><\/p>\n<\/div>\n\n\n\n

\n

Our latest generation Sapphire 3 obtained approval from PMDA in January.<\/p>\n\n\n\n

ScoreFlex PTA received FDA 510(k) clearance in May. <\/p>\n\n\n\n

COMBO Plus dual therapy stent obtained approval from PMDA.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

2020<\/strong><\/p>\n<\/div>\n\n\n\n

\n

Sapphire 3 and Sapphire NC 24 received CE Mark in March.<\/p>\n\n\n\n

We acquired our distributor in Switzerland in August to actively expand our direct sales network.<\/p>\n\n\n\n

COMBO dual therapy stent obtained NMPA approval in August.<\/p>\n\n\n\n

We formed a strategic joint venture with Products & Features International, LDA for  the  development, manufacturing and distribution of  structural heart products in certain countries in Asia Pacific regions in October.<\/p>\n\n\n\n

Sapphire II Pro OTW version and Jade PTA 14\u201d\/18\u201d\/35\u201d OTW series were launched in the United States.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

2021<\/strong><\/p>\n<\/div>\n\n\n\n

\n

We first opened to third party investments and completed two rounds of financing within a few months, raising US$202.5 million in aggregate from well-known institutional investors and family offices. <\/p>\n\n\n\n

We established our sales team in the Mainland of China.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

2022<\/strong><\/p>\n<\/div>\n\n\n\n

\n

We were successfully listed on HKEx and raised approx. HK$481 million.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

2023<\/strong><\/p>\n<\/div>\n\n\n\n

\n

Our Group acquired eucatech AG, a German medical engineering company, to enrich product offerings.<\/p>\n\n\n\n

Our Group acquired PT Revass, an Indonesia distributor, and SJ Medicare, a South Korean distributor to further strengthen the sales network.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

2024<\/strong><\/p>\n<\/div>\n\n\n\n

\n

We launched a high-capacity logistics center in the Netherlands.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

2025<\/strong><\/p>\n<\/div>\n\n\n\n

\n

We acquired our distributor in Taiwan to enhance our direct sales network in Taiwan.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/p>\n<\/div><\/div>\n\n\n\n

\n

Executive Directors and Senior Management<\/h3>\n\n\n\t
\n\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"photo\n\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\tDavid CHIEN<\/span><\/strong>\n\t\t\t\t\t\t\t<\/p>\n\t\t\t\t\t\t\t

Chairman, Executive Director and Chief Executive Officer<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tRead more<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\t\t\t\t\t\t\t

Mr. David CHIEN<\/strong> (\u9322\u6c38\u52db)<\/strong> is the Chairman, Executive Director and Chief Executive Officer of OrbusNeich. Mr. Chien joined OrbusNeich in February 2000 and is primarily responsible for overseeing the overall strategic planning and policy execution of OrbusNeich.<\/p>\n

Mr. Chien has around 31 years of experience in the medical devices industry, and was the director of Cordis-Neich Limited from January 1994 to October 1997. He was a director of Tysan Holdings Limited, a company listed on the Main Board of the Stock Exchange (stock code: 0687), from November 1997 to January 2014. Mr. Chien has been the trustee of the Chien Foundation since January 1997 and the governor of KFoundation since July 2019. Mr. Chien was elected as a member of the Board of Trustees of Chung Chi College, the Chinese University of Hong Kong, in 2020.<\/p>\n

Mr. Chien studied at York University in Canada.<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"photo\n\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\tDenise LAU<\/span><\/strong>\n\t\t\t\t\t\t\t<\/p>\n\t\t\t\t\t\t\t

Executive Director and Chief Operating Officer<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tRead more<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\t\t\t\t\t\t\t

Ms. Kwai Ching Denise LAU (\u5289\u6842\u798e)<\/strong> is the Executive Director and Chief Operating Officer of OrbusNeich. She is primarily responsible for leading, overseeing and supervising the operation of OrbusNeich.<\/p>\n

Ms. Lau has more than 25 years of legal, business operation and management experience. Ms. Lau was trained and admitted as a solicitor in Hong Kong in 1999, and was subsequently admitted to practice law in England and Wales and the state of New York in 2000 and 2001, respectively. She worked as an attorney in Paul, Weiss, Rifkind, Wharton & Garrison from 2000 to 2006 and joined Morgan Stanley in February 2006, and left as managing director in April 2015. She joined OrbusNeich as the general counsel and senior vice president on April 3, 2018.<\/p>\n

Ms. Lau obtained her Bachelor of Laws degree from The University of Hong Kong in 1996 and obtained her Postgraduate Certificate in Laws from the same university in 1997. Ms. Lau also obtained her master\u2019s degree in international economic law from the University of Warwick in the United Kingdom in January 2001. Ms. Lau has been the Vice President of the Fuyang Association of Enterprises with Foreign Investment (\u5bcc\u967d\u5916\u8cc7\u4f01\u696d\u5354\u6703) since March 2023.<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"photo\n\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\tJason CHEN<\/span><\/strong>\n\t\t\t\t\t\t\t<\/p>\n\t\t\t\t\t\t\t

Executive Director, Chief Financial Officer and Company Secretary<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tRead more<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\t\t\t\t\t\t\t

Mr. Wing Shing Jason CHEN (\u9673\u6cf3\u6210) <\/strong>is the Executive Director, Chief Financial Officer and Company Secretary of OrbusNeich.<\/p>\n

Mr. Chen has around 21 years of experience in auditing, accounting and corporate finance. He joined PricewaterhouseCoopers in December 2003 in the assurance practice and left as senior manager in February 2017. Before joining OrbusNeich, Mr. Chen worked in corporate finance in property development and investment sector in the PRC. Mr. Chen joined our OrbusNeich in April 2017 as the financial controller, and was later promoted as the Chief Financial Officer of OrbusNeich in January 2018.<\/p>\n

Mr. Chen obtained his bachelor\u2019s degree in business administration, concentrating in financial engineering from The Chinese University of Hong Kong with first class honors in December 2003. He is a certified public accountant in Hong Kong, the State of Washington and the State of Delaware of the United States. He is also a charter holder of the Chartered Financial Analyst Institute.<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\n\t<\/div>\n\t<\/div><\/div>\n\n\n\n

\n

Non-Executive Directors<\/strong><\/strong><\/h3>\n\n\n\t
\n\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\n\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\tPeter LEUNG<\/span><\/strong>\n\t\t\t\t\t\t\t<\/p>\n\t\t\t\t\t\t\t

Non-executive Director<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tRead more<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\t\t\t\t\t\t\t

Mr. Ting San Peter Lionel LEUNG (<\/strong>\u6881\u9f0e\u65b0<\/strong>)<\/strong> is a Non-executive Director of OrbusNeich.<\/p>\n

Mr. Leung has over 37 years of experience in developing and managing projects in the Mainland China and overseas. He started his career as an assistant architect in 1985 and became a project manager in 1991. Since then, he assumed various management positions in Hong Kong listed property developers. He joined Hang Lung Properties Limited, a company listed on the Main Board of the Stock Exchange (stock code: 00101), in January 2014 and became their Director-Project Management from 2017 until his departure in May 2024. He joined Galaxy Entertainment Group Limited, a company listed on the Main Board of the Stock Exchange (stock code: 0027), in May 2024 as Executive Vice President, Project Development.<\/p>\n

Mr. Leung obtained a Postgraduate Diploma in Construction Project Management from The University of Hong Kong in July 1995, a Bachelor of Architecture degree and a Bachelor of Science (Architecture) degree from McGill University, Canada in June 1984 and June 1985, respectively. He is also a Registered Architect in Hong Kong, a member of the Hong Kong Institute of Architects and holds a PRC Class 1 Registered Architect Qualification.<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\n\t<\/div>\n\t\n\n\n

Independent Non-Executive Directors<\/strong><\/h3>\n\n\n\t
\n\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\n\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\tYip Keung CHAN<\/span><\/strong>\n\t\t\t\t\t\t\t<\/p>\n\t\t\t\t\t\t\t

Independent Non-executive Director<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tRead more<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\t\t\t\t\t\t\t

Mr. Yip Keung CHAN (<\/strong>\u9673\u696d\u5f37<\/strong>)<\/strong> is an Independent Non-executive Director of OrbusNeich and is primarily responsible for supervising and providing independent judgment to our Board.<\/p>\n

Mr. Chan has more than 19 years of experience in financial reporting, auditing, corporate finance, capital management and corporate governance. He started working in PricewaterhouseCoopers in September 2005 and was promoted as manager in October 2010. Mr. Chan was the finance manager of Mapletree Hong Kong Management Limited under Temasek of Singapore from November 2011 to April 2015, specialized in real estate investment trusts sector. He was the chief financial officer of the Pine Care Group Limited (a company previously listed on the Stock Exchange with stock code 1989 and was delisted in February 2024) from April 2015 to October 2020 and is currently the chief executive officer and executive director of the aforementioned group. He was appointed by Chinachem Group as the Director of Elderly Care Services in November 2022.<\/p>\n

Mr. Chan obtained his Bachelor of Business Administration degree from the Chinese University of Hong Kong in 2005 and masters\u2019 degree in corporate governance from Hong Kong Polytechnic University in 2017. He is a certified public accountant in Hong Kong, a fellow of the Hong Kong Institute of Certified Public Accountant, and an associate member of the Hong Kong Institute of Chartered Secretaries and the Chartered Governance Institute.<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\n\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\tKa Keung LAU BBS, MH, JP<\/span><\/strong>\n\t\t\t\t\t\t\t<\/p>\n\t\t\t\t\t\t\t

Independent Non-executive Director<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tRead more<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\t\t\t\t\t\t\t

Mr. Ka Keung LAU (<\/strong>\u6a13\u5bb6\u5f37<\/strong>) <\/strong>BBS, MH, JP<\/em><\/strong>,<\/strong> is an Independent Non-executive Director of OrbusNeich and is primarily responsible for supervising and providing independent judgment to our Board.<\/p>\n

Mr. Lau has around 27 years of experience in business management. Mr. Lau held several positions in the Nameson Group from August 1999 to March 2013, including information technology manager, vice president, and executive director. From August 2015 to April 2018, Mr. Lau served as a non-executive director in Nameson Holdings Limited (\u5357\u65cb\u63a7\u80a1\u6709\u9650\u516c\u53f8), a company listed on the Main Board of the Stock Exchange (stock code: 1982). Mr. Lau has served as an executive director and chief executive officer of Million Cities Holdings Limited (\u842c\u57ce\u63a7\u80a1\u6709\u9650\u516c\u53f8) (\u201cMillion Cities\u201d), a company listed on the Main Board of the Stock Exchange (stock code: 2892) since 2016, and has assumed various directorships in subsidiaries of Million Cities. Mr. Lau has been appointed as an independent non-executive director of Tianjin Development Holdings Limited, a company listed on the Main Board of the Stock Exchange (stock code: 882), since March 30, 2023 and West China Cement Limited, a company listed on the Main Board of the Stock Exchange (stock code: 2233), since March 24, 2025.<\/p>\n

Mr. Lau received his Bachelor\u2019s degree from Manchester Metropolitan University, the United Kingdom in July 1997 and obtained his master\u2019s degree in business administration from University of Leicester, the United Kingdom in July 2008. Mr. Lau has served as deputy to the 14th National People\u2019s Congress (\u7b2c\u5341\u56db\u5c46\u5168\u570b\u4eba\u6c11\u4ee3\u8868\u5927\u6703), national committee member of the 13th Chinese People Political Consultative Conference in the PRC (\u4e2d\u570b\u4eba\u6c11\u653f\u6cbb\u5354\u5546\u6703\u8b70\u7b2c\u5341\u4e09\u5c46\u5168\u570b\u59d4\u54e1\u6703), executive committee member of the 14th Tianjin Committee of Chinese People\u2019 Political Consultative Conference (\u4e2d\u570b\u4eba\u6c11\u653f\u6cbb\u5354\u5546\u6703\u8b70\u5929\u6d25\u5e02\u7b2c\u5341\u56db\u5c46\u5e38\u52d9\u59d4\u54e1\u6703) and Vice Chairman of Tianjin Federation of Industry and Commerce (\u5929\u6d25\u5e02\u5de5\u5546\u696d\u806f\u5408\u6703). Mr. Lau is also the chairman of the 28th Hong Kong United Youth Association (\u9999\u6e2f\u9752\u5e74\u806f\u6703).<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\n\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\tGloria TAM<\/span><\/strong>\n\t\t\t\t\t\t\t<\/p>\n\t\t\t\t\t\t\t

Independent Non-executive Director<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tRead more<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\t\t\t\t\t\t\t

Dr. Lai Fan Gloria TAM (<\/strong>\u8b5a\u9e97\u82ac<\/strong>)<\/strong> is an Independent Non-executive Director of OrbusNeich and is primarily responsible for supervising and providing independent judgment to our Board.<\/p>\n

Dr. Tam has around 41 years of experience in the healthcare industry. She started working as a Medical and Health Officer in the Medical and Health Department, Hong Kong Government in January 1984 and became Deputy Director of Health in July 2007. She was also the Controller of Centre for Food Safety in Hong Kong from June 2012 to June 2017. She is the founder of 3 Srs Company (\u4ee8\u4ec1\u4e00\u4eba\u6709\u9650\u516c\u53f8), a public health consultancy cum investment firm, since June 2020. Dr. Tam served as an independent non-executive director of Zhaoke Ophthalmology Limited, a company listed on the Main Board of the Stock Exchange (stock code: 6622), from April 2021 to April 2022. Dr. Tam served as an independent non-executive director of Arta TechFin Corporation Limited (formerly known as Freeman FinTech Corporation Limited), a company listed on the Main Board of the Stock Exchange (stock code: 279), from October 2021 to September 2024.<\/p>\n

Dr. Tam obtained her Bachelor of Medicine and Bachelor of Surgery degrees from The University of Hong Kong in 1983 and Master of Medicine (Public Health) from the National University of Singapore in May 1993. She was elected as a Fellow of the Faculty of Public Health of the Royal College of Physicians, United Kingdom in February 2007.<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\n\t<\/div>\n\t<\/div><\/div>\n\n\n\n

\n

Senior Management<\/strong><\/h3>\n\n\n\t
\n\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"photo\n\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\tAlain KHAIR<\/span><\/strong>\n\t\t\t\t\t\t\t<\/p>\n\t\t\t\t\t\t\t

Chief Commercial Officer<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tRead more<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\t\t\t\t\t\t\t

Mr. Alain Djamel KHAIR<\/strong> is the Chief Commercial Officer of OrbusNeich, responsible for overseeing global commercial activities, steering the directions of market penetration of OrbusNeich\u2019s products, and managing the development and the implementation of all commercial strategies. He also directs and oversees OrbusNeich\u2019s growth matrix, distribution channels and the deployment of OrbusNeich sales and marketing resources.<\/p>\n

Mr. Khair has around 22 years of sales and marketing experience in the medical device industry. He held several management roles including products advisor, territory sales manager, clinical specialist for Eastern Europe and Middle East at Abbott Laboratories Limited from 2003 to 2008. He joined OrbusNeich as regional product manager in January 2008 and was the vice president in sales of EMEA from May 1, 2017 to December 31, 2019.<\/p>\n

Mr. Khair received his registered nurse qualification from the Nursing & Midwifery Council in the United Kingdom in May 2002 and obtained his Master of Business Administration degree in marketing from University of Leicester in the United Kingdom in 2013.<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"photo\n\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\tEric DONG<\/span><\/strong>\n\t\t\t\t\t\t\t<\/p>\n\t\t\t\t\t\t\t

Vice President of Manufacturing<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tRead more<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\t\t\t\t\t\t\t

Mr. Yuanli Eric DONG (<\/strong>\u8463\u5143\u5229<\/strong>)<\/strong> is the Vice President of Manufacturing of OrbusNeich and the General Manager of OrbusNeich Shenzhen, responsible for overall manufacturing activities.<\/p>\n

Bringing over three decades of experience in the manufacturing industry and more than 20 years in the medical device sector, Mr. Dong has been involved in technical, management, and R&D activities in mechanics, electronics, home appliances and medical devices.<\/p>\n

Mr. Dong joined OrbusNeich Shenzhen in 2000 as a Senior Engineer. Since then, he has held various management roles, including Manager of Manufacturing Engineering and Product Development, Manager of Technical Services and Manager of Material Management. He was promoted as Director of Plant Management in 2015 and the Director of Operations & General Manager of OrbusNeich Shenzhen in 2020. He was further promoted to Vice President of Manufacturing of OrbusNeich in 2021, where he managed OrbusNeich\u2019s manufacturing operations and served as the General Manager of OrbusNeich Shenzhen.<\/p>\n

Mr. Dong obtained his bachelor\u2019s degree in engineering, majoring in mechanical manufacturing processes and equipment, from the Taiyuan Mechanics Institute (now North University of China) in 1989.<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\n\t<\/div>\n\t\n\n\n

<\/p>\n<\/div><\/div>\n\n\n\n

\n
\n
\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Worldwide Locations<\/h3>\n\n\n\n

We have our research and development teams in both Shenzhen, China, and Tokyo, Japan and our production facilities in Shenzhen, China, Hoevelaken, the Netherlands and Weil am Rhein, Germany.<\/p>\n\n\n\n

OrbusNeich is represented throughout the world. Headquartered in Hong Kong, China, our direct sales locations are in France, Germany, Hong Kong, Macau, Monaco, Indonesia, Japan, Malaysia, Singapore, Spain, Switzerland, and Taiwan, along with a distributor network covering over 70 countries and regions across six continents.<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n

\n\n\n\n
\n

Headquarters, Research & Development and Production Facilities<\/h3>\n\n\n\n
\n
\n
\"\"<\/figure>\n\n\n\n
<\/div>\n\n\n\n

Hong Kong, China<\/h4>\n\n\n\n

Corporate Headquarters<\/strong><\/strong><\/p>\n\n\n\n

Units 303 & 305, 3\/F, Building 20E,
Hong Kong Science Park,
Shatin, N.T.
Hong Kong, China<\/p>\n\n\n\n

Tel:<\/strong> +852 2802 2288
<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n\n\n\n
<\/div>\n\n\n\n

Shenzhen, China<\/h4>\n\n\n\n

Research & Development and Production Facility<\/strong><\/strong><\/p>\n\n\n\n

1 Jinkui Road, Futian Free Trade Zone, Shenzhen, 518038, China<\/p>\n\n\n\n

<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n\n\n\n
<\/div>\n\n\n\n

Hoevelaken, The Netherlands<\/h4>\n\n\n\n

EMEA Regional Headquarters<\/strong>
and Production Facility<\/strong>
<\/strong>
Drs. W. van Royenstraat 5,
3871 AN, Hoevelaken,
The Netherlands<\/p>\n\n\n\n

<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n\n\n\n
<\/div>\n\n\n\n

Weil am Rhein, Germany<\/h4>\n\n\n\n

Production Facility<\/strong><\/strong><\/strong><\/p>\n\n\n\n

Rebgartenweg 27,
79576 Weil am Rhein,
Germany<\/p>\n\n\n\n



<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n\n\n\n
<\/div>\n\n\n\n

Tokyo, Japan<\/h4>\n\n\n\n

Advanced Technology Laboratory<\/strong><\/p>\n\n\n\n

Kanagawa Science Park East Wing 412, 3-2-1 Sakado, Takatsu-Ku, Kawasaki-city

<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"

Our Mission OrbusNeich designs and delivers innovative solutions for the treatment of vascular disease that improve patients\u2019 quality of life. Our commitment is driven by Integrity, Passion, Innovation, and Performance. These respect the foundation of our core values that shape and reflect the company\u2019s identity. G-70-1095 Rev02 History OrbusNeich is a multinational medical device company… Read more »<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":50,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_themeisle_gutenberg_block_has_review":false,"footnotes":""},"class_list":["post-3615","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nAbout Us - OrbusNeich<\/title>\n<meta name=\"description\" content=\"Find out about OrbusNeich's history, board of directors, executive management and our worldwide locations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/orbusneich.com\/us\/about-us\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"About Us - OrbusNeich\" \/>\n<meta property=\"og:description\" content=\"Find out about OrbusNeich's history, board of directors, executive management and our worldwide locations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/orbusneich.com\/us\/about-us\/\" \/>\n<meta property=\"og:site_name\" content=\"OrbusNeich\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T09:17:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/orbusneich.com\/wp-content\/uploads\/2020\/09\/hcp-banner.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"792\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@OrbusNeich\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/orbusneich.com\/us\/about-us\/\",\"url\":\"https:\/\/orbusneich.com\/us\/about-us\/\",\"name\":\"About Us - OrbusNeich\",\"isPartOf\":{\"@id\":\"https:\/\/orbusneich.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/orbusneich.com\/us\/about-us\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/orbusneich.com\/us\/about-us\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/orbusneich.com\/wp-content\/uploads\/2020\/09\/hcp-banner.jpg\",\"datePublished\":\"2020-05-06T15:35:08+00:00\",\"dateModified\":\"2026-04-01T09:17:27+00:00\",\"description\":\"Find out about OrbusNeich's history, board of directors, executive management and our worldwide locations.\",\"breadcrumb\":{\"@id\":\"https:\/\/orbusneich.com\/us\/about-us\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/orbusneich.com\/us\/about-us\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/orbusneich.com\/us\/about-us\/#primaryimage\",\"url\":\"https:\/\/orbusneich.com\/wp-content\/uploads\/2020\/09\/hcp-banner.jpg\",\"contentUrl\":\"https:\/\/orbusneich.com\/wp-content\/uploads\/2020\/09\/hcp-banner.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/orbusneich.com\/us\/about-us\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/orbusneich.com\/us\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"About Us\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/orbusneich.com\/#website\",\"url\":\"https:\/\/orbusneich.com\/\",\"name\":\"OrbusNeich\",\"description\":\"Forging new paths in the treatment of vascular diseases\",\"publisher\":{\"@id\":\"https:\/\/orbusneich.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/orbusneich.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/orbusneich.com\/#organization\",\"name\":\"OrbusNeich Medical Company Limited\",\"url\":\"https:\/\/orbusneich.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/orbusneich.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/orbusneich.com\/wp-content\/uploads\/2020\/05\/orbusneich-logo.svg\",\"contentUrl\":\"https:\/\/orbusneich.com\/wp-content\/uploads\/2020\/05\/orbusneich-logo.svg\",\"width\":460,\"height\":74,\"caption\":\"OrbusNeich Medical Company Limited\"},\"image\":{\"@id\":\"https:\/\/orbusneich.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/OrbusNeich\",\"https:\/\/www.linkedin.com\/company\/orbusneich-medical\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"About Us - OrbusNeich","description":"Find out about OrbusNeich's history, board of directors, executive management and our worldwide locations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/orbusneich.com\/us\/about-us\/","og_locale":"en_US","og_type":"article","og_title":"About Us - OrbusNeich","og_description":"Find out about OrbusNeich's history, board of directors, executive management and our worldwide locations.","og_url":"https:\/\/orbusneich.com\/us\/about-us\/","og_site_name":"OrbusNeich","article_modified_time":"2026-04-01T09:17:27+00:00","og_image":[{"width":2000,"height":792,"url":"https:\/\/orbusneich.com\/wp-content\/uploads\/2020\/09\/hcp-banner.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@OrbusNeich","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/orbusneich.com\/us\/about-us\/","url":"https:\/\/orbusneich.com\/us\/about-us\/","name":"About Us - OrbusNeich","isPartOf":{"@id":"https:\/\/orbusneich.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/orbusneich.com\/us\/about-us\/#primaryimage"},"image":{"@id":"https:\/\/orbusneich.com\/us\/about-us\/#primaryimage"},"thumbnailUrl":"https:\/\/orbusneich.com\/wp-content\/uploads\/2020\/09\/hcp-banner.jpg","datePublished":"2020-05-06T15:35:08+00:00","dateModified":"2026-04-01T09:17:27+00:00","description":"Find out about OrbusNeich's history, board of directors, executive management and our worldwide locations.","breadcrumb":{"@id":"https:\/\/orbusneich.com\/us\/about-us\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/orbusneich.com\/us\/about-us\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/orbusneich.com\/us\/about-us\/#primaryimage","url":"https:\/\/orbusneich.com\/wp-content\/uploads\/2020\/09\/hcp-banner.jpg","contentUrl":"https:\/\/orbusneich.com\/wp-content\/uploads\/2020\/09\/hcp-banner.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/orbusneich.com\/us\/about-us\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/orbusneich.com\/us\/"},{"@type":"ListItem","position":2,"name":"About Us"}]},{"@type":"WebSite","@id":"https:\/\/orbusneich.com\/#website","url":"https:\/\/orbusneich.com\/","name":"OrbusNeich","description":"Forging new paths in the treatment of vascular diseases","publisher":{"@id":"https:\/\/orbusneich.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/orbusneich.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/orbusneich.com\/#organization","name":"OrbusNeich Medical Company Limited","url":"https:\/\/orbusneich.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/orbusneich.com\/#\/schema\/logo\/image\/","url":"https:\/\/orbusneich.com\/wp-content\/uploads\/2020\/05\/orbusneich-logo.svg","contentUrl":"https:\/\/orbusneich.com\/wp-content\/uploads\/2020\/05\/orbusneich-logo.svg","width":460,"height":74,"caption":"OrbusNeich Medical Company Limited"},"image":{"@id":"https:\/\/orbusneich.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/OrbusNeich","https:\/\/www.linkedin.com\/company\/orbusneich-medical\/"]}]}},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/orbusneich.com\/us\/wp-json\/wp\/v2\/pages\/3615","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/orbusneich.com\/us\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/orbusneich.com\/us\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/orbusneich.com\/us\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/orbusneich.com\/us\/wp-json\/wp\/v2\/comments?post=3615"}],"version-history":[{"count":165,"href":"https:\/\/orbusneich.com\/us\/wp-json\/wp\/v2\/pages\/3615\/revisions"}],"predecessor-version":[{"id":26431,"href":"https:\/\/orbusneich.com\/us\/wp-json\/wp\/v2\/pages\/3615\/revisions\/26431"}],"wp:attachment":[{"href":"https:\/\/orbusneich.com\/us\/wp-json\/wp\/v2\/media?parent=3615"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}